Literature DB >> 21654843

The peptide-binding motif of HLA-DR8 shares important structural features with other type 1 diabetes-associated alleles.

L Muixí1, M Gay, P M Muñoz-Torres, C Guitart, J Cedano, J Abian, I Alvarez, D Jaraquemada.   

Abstract

The objective of this study was to characterize the peptide-binding motif of the major histocompatibility complex (MHC) class II HLA-DR8 molecule included in the type 1 diabetes-associated haplotype DRB1(*)0801-DQA1(*)0401/DQB1(*)0402 (DR8-DQ4), and compare it with that of other diabetes-associated MHC class II alleles; DR8-bound peptides were eluted from an HLA-DR homozygous lymphoblastoid cell line. The repertoire was characterized by peptide sequencing using a LTQ ion trap mass spectrometer coupled to a multidimensional liquid chromatography system. After validation of the spectra identification, the definition of the HLA-DR8 peptide-binding motif was achieved from the analysis of 486 natural ligands, based on serial alignments of all possible HLA-DR-binding cores. The DR8 motif showed a strong similarity with the peptide-binding motifs of other MHC class II diabetes-associated alleles, HLA-DQ8 and H-2 I-A(g7). Similar to HLA-DQ8 and H-2 I-A(g7), HLA-DR8 preferentially binds peptides with an acidic residue at position P9 of the binding core, indicating that DR8 is the susceptibility component of the DR8-DQ4 haplotype. Indeed, some DR8 peptides were identical to peptides previously identified as DQ8- or I-A(g7) ligands, and several diabetes-specific peptides associated with DQ8 or I-A(g7) could theoretically bind to HLA-DR8. These data further strengthen the association of HLA-DR8 with type I diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21654843     DOI: 10.1038/gene.2011.26

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  9 in total

1.  PRBAM: a new tool to analyze the MHC class I and HLA-DR anchor motifs.

Authors:  Anna Mestre-Ferrer; Erika Scholz; Jepi Humet-Alsius; Iñaki Alvarez
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

2.  Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08:01 and DRB1*11:01 Is predicted by their structural motifs and correlates with disease risk.

Authors:  I-Ting Chow; Eddie A James; Theresa J Gates; Venus Tan; Antonis K Moustakas; George K Papadopoulos; William W Kwok
Journal:  J Immunol       Date:  2013-03-29       Impact factor: 5.422

3.  Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation.

Authors:  Catia S Verbeke; Susana Gordo; David A Schubert; Sarah A Lewin; Rajiv M Desai; Jessica Dobbins; Kai W Wucherpfennig; David J Mooney
Journal:  Adv Healthc Mater       Date:  2017-01-24       Impact factor: 9.933

4.  HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression.

Authors:  Jennifer Schloss; Riyasat Ali; Jeremy J Racine; Harold D Chapman; David V Serreze; Teresa P DiLorenzo
Journal:  J Immunol       Date:  2018-04-09       Impact factor: 5.422

5.  Membranal and Blood-Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition.

Authors:  Danilo Ritz; Emiliano Sani; Hanna Debiec; Pierre Ronco; Dario Neri; Tim Fugmann
Journal:  Proteomics       Date:  2018-03-14       Impact factor: 3.984

6.  IgG Epitopes Processed and Presented by IgG+ B Cells Induce Suppression by Human Thymic-Derived Regulatory T Cells.

Authors:  Li-En Hsieh; John Sidney; Jane C Burns; David L Boyle; Gary S Firestein; Yoav Altman; Alessandro Sette; Alessandra Franco
Journal:  J Immunol       Date:  2021-02-12       Impact factor: 5.422

7.  Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.

Authors:  Li-En Hsieh; Jaeyoon Song; Adriana H Tremoulet; Jane C Burns; Alessandra Franco
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

8.  Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires.

Authors:  Erika Margaret Scholz; Miguel Marcilla; Xavier Daura; David Arribas-Layton; Eddie A James; Iñaki Alvarez
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

9.  Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report.

Authors:  Andrea Aran; Vicente Peg; Rosa Maria Rabanal; Cristina Bernadó; Esther Zamora; Elisa Molina; Yago A Arribas; Joaquín Arribas; José Pérez; Carme Roura-Mir; Montserrat Carrascal; Javier Cortés; Mercè Martí
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.